Agenus

Agenus Pivots Oncology Strategy Amidst Broader Regulatory Shifts in Pharma and Biotech

Agenus's strategic pivot in oncology, backed by $340M, targets a $7B neoadjuvant colon cancer market, signaling a shift to high-value segments. Concurrently, FDA decisions on BMS's mezigdomide and expanded use for Pfizer's Padcev reshape oncology treatment. Apnimed faces heightened FDA scrutiny on "clinically meaningful benefit" for Oxnimbi, while Oxford's Ebola vaccine advances, emphasizing global health preparedness.